Chemoresistance as a function of the pretherapy tumor burden and the chemotherapy regimen administered: Differences observed with 2 current chemotherapy regimens for advanced hodgkin lymphoma

Clinical Lymphoma, Myeloma and Leukemia

Volumn 11, Issue 5, 2011, Pages 396-402

  Gobbi, Paolo G ^a   Valentino, Francesco ^a   Bassi, Emilio ^a   Coriani, Chiara ^b   Merli, Francesco ^b   Bonfante, Valeria ^c   Marchianò, Alfonso ^c   Gallamini, Andrea ^d   Bolis, Silvia ^e   Stelitano, Caterina ^f   Levis, Alessandro ^g   Federico, Massimo ^h   Angrilli, Francesco ⁱ   Di Giulio, Giuseppe ^a   Corazza, Gino R ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b S MARIA NUOVA HOSPITAL   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d S CROCE E CARLE HOSPITAL   (Italy)

^e SAN GERARDO HOSPITAL   (Italy)

^f BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^g C Arrigo Children's Hospital   (Italy)

^h UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

ⁱ SPIRITO SANTO HOSPITAL   (Italy)

Author keywords

Chemoresistance; Chemotherapy; Hodgkin lymphoma; Tumor burden

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE SULFATE; ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; BODY SURFACE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CHEMORESISTANCE; COMPUTER ASSISTED TOMOGRAPHY; DRUG TREATMENT FAILURE; FEMALE; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONCOLOGICAL PARAMETERS; PREDICTOR VARIABLE; RELATIVE TUMOR BURDEN; RETROSPECTIVE STUDY; TREATMENT RESPONSE; TUMOR VOLUME; AGED; CANCER STAGING; COMPARATIVE STUDY; DRUG EFFECT; DRUG RESISTANCE; MIDDLE AGED; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84856203428     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2011.04.008     Document Type: Article

References (25)

1. Santoro A, Bonadonna G, Valagussa P, et al. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 1987; 5:27-37. (Pubitemid 17007853)
2. Canellos JM, Anderson JR, Propert K, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, orMOPP alternating with ABVD.N Engl J Med 1992; 327:1478-84.
3. Duggan DB, Petroni GR, Johnson JL, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an Intergroup trial. J Clin Oncol 2003; 21:607-14. (Pubitemid 46621893)
4. Canellos GP, Niedzwiecki D. Long-term follow-up of Hodgkin's disease trial. N Engl J Med 2002; 346:1417-8. (Pubitemid 34754624)
5. Horning SJ, Hoppe RT, Breslin S, et al. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol 2002; 20:630-7. (Pubitemid 34111368)
6. Gobbi PG, Levis A, Chisesi T, et al. ABVD, versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate-and advanced-stage Hodgkin's lymphoma. J Clin Oncol 2005; 23:9198-207.
7. Johnson PW, Redford JA, Cullen, MH, et al. Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group. J Clin Oncol 2005; 23:9208-18.
8. Viviani S, Bonfante V, Santoro A, et al. Long-term results of an intensive regimen: VEBEP plus involved-field radiotherapy in advanced Hodgkin's disease. Cancer J Sci Am 1999; 5:275-82. (Pubitemid 29471532)
9. Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEA-COPP chemotherapy compared with COPP/ABVD for advanced Hodgkin's disease. N Engl J Med 2003; 348:2386-95. (Pubitemid 36682817)
10. Engert A, Franklin J, Diehl V. Long-term follow-up of BEACOPP escalated chemotherapy in patients with advance-stage Hodgkin lymphoma on behalf of the German Hodgkin Study Group. Blood 2007; 110 (suppl 11): abstr 211.
11. Federico M, Luminari S, Iannitto E, et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol 2009; 27:805-11.
12. Gianni AM, Rambaldi A, Zinzani PL, et al. Comparable 3-year outcome following ABVD or BEACOPP first-line chemotherapy, plus pre-planned high-dose slavage, in advanced Hodgkin lymphoma (HL): a randomized trial of the Michelangelo, GITIL and IIL cooperative groups. J Clin Oncol 2008; 26 (suppl 15); abstr 8506.
13. Cheson BD, Horning SJ, Coiffier B, et al. Report of an International Workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17:1244-63.
14. Hasenclever D, Diehl V; for the International Prognostic Factor Project on Advanced Hodgkin's Disease. A prognostic score to predict tumor control in advanced Hodgkin's disease. N Engl J Med 1998; 339:1506-14.
15. Gobbi PG, Ghirardelli ML, Solcia M, et al. Image-aided estimate of tumor burden in Hodgkin's disease: evidence of its primary prognostic importance. J Clin Oncol 2001; 19:1388-94. (Pubitemid 32202545)
16. Gobbi PG, Broglia C, Di Giulio G, et al. The clinical value of tumor burden at diagnosis in Hodgkin lymphoma. Cancer 2004; 101:1824-34. (Pubitemid 39314746)
17. Wickramasinghe SN. Human Bone Marrow. Oxford: United Kingdom: Blackwell Scientific Publications; 1976:211-6.
18. Devine BJ. Gentamicin therapy. Drug Intell Clin Pharm 1974; 16:274-80.
19. Armitage P, Berry G. Statistical Methods in Medical Research. 2nd ed. Oxford, United Kingdom: Blackwell Scientific Publications; 1987:396-9.
20. Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of breast cancer. J Clin Oncol 1984; 2:1281-8. (Pubitemid 15202705)
21. Fisher RI, DeVita VT, Hubbard SM, et al. Prolonged disease-free survival in Hodg-kin's disease with MOPP reinduction after first relapse. Ann Intern Med 1979; 90:761-3. (Pubitemid 9182460)
22. Viviani S, Santoro A, Negretti E, et al. Salvage chemotherapy in Hodgkin's disease. Results in patients relapsing more than twelve months after first complete remission. Ann Oncol 1990; 1:123-7. (Pubitemid 20215453)
23. Goldie JH, Coldman AJ. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979; 63:1727-33. (Pubitemid 10138923)
24. Norton L, Simon R. Tumor size, sensitivity to therapy, and the design of treatment schedules. Cancer Treat Rep 1977; 61: 1307-17. (Pubitemid 8204100)
25. Hasenclever D. The disappearance of prognostic factors in Hodgkin's disease. Ann Oncol 2002; 13 (suppl 1):75-8. (Pubitemid 34567405)